The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/appi.ps.20220375

Objective:

An expert consensus approach was used to determine the adequacy of children’s psychopharmacology and to examine whether adequacy varied by demographic or clinical characteristics.

Methods:

Data were from the baseline interview of 601 children, ages 6–12 years, who had visited one of nine outpatient mental health clinics and participated in the Longitudinal Assessment of Manic Symptoms study. Children and parents were interviewed with the Kiddie Schedule for Affective Disorders and Schizophrenia and the Service Assessment for Children and Adolescents to assess the child’s psychiatric symptoms and lifetime mental health services use, respectively. An expert consensus approach informed by published treatment guidelines was used to determine the adequacy of children’s psychotropic medication treatment.

Results:

Black children (compared with White children; OR=1.84, 95% CI=1.53–2.23) and those with anxiety disorders (vs. no anxiety disorder; OR=1.55, 95% CI=1.08–2.20) were more likely to receive inadequate pharmacotherapy; those whose caregivers had a bachelor’s degree or more education (vs. those who had a high school education, general equivalency diploma, or less than high school education; OR=0.74, 95% CI=0.61–0.89) were less likely to receive inadequate pharmacotherapy.

Conclusions:

The consensus rater approach permitted use of published treatment efficacy data and patient characteristics (e.g., age, diagnoses, history of recent hospitalizations, and psychotherapy) to assess adequacy of pharmacotherapy. These results replicate findings of racial disparities reported in previous research using traditional methods to determine treatment adequacy (e.g., with a minimum number of treatment sessions) and highlight the continued need for research on racial disparities and strategies to improve access to high-quality care.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.